Terumo Corp. (TYO:4543) said yesterday it tapped Rob DeRyke as its new CV group prez & CEO, effective April 1, 2017, succeeding a retiring Mark Sutter. Prior to his appointment, DeRyke operated as Terumo CV group electromechanical systems division prez, the company said. “Under his leadership, Rob brought stability and improved profitability to the business,” Terumo […]
Terumo
Medtech stocks: the best and worst of Q1 2017
More than four-fifths of the 100 largest medical device companies in the world saw their stock prices increase during the first three months of 2017, according to a Medical Design & Outsourcing analysis of how the stocks of our Big 100 companies are faring. The situation suggests that even with the uncertainty around what the […]
Terumo’s MicroVention touts low adverse composite outcomes in HydroCoil study
Terumo Corp. (TYO:4543) subsidiary MicroVention today released results from a study of its HydroCoil embolic system, touting that the trial met its primary and secondary endpoints and showed low adverse composite outcomes. The 513-patient prospective, randomized, controlled trial aimed to explore the use of the HydroCoil embolic system for treating endovascular aneurysms compared to bare platinum coils, […]
Terumo, Xenex ink Japanese distro deal for LightStrike room disinfection robot
Terumo Corp. (TYO:4543) said today it inked a Japanese distribution deal with Xenex to distribute its Xenex LightStrike Germ-Zapping Robots in the region. The LightStrike device is designed to use pulsed xenon ultraviolet room disinfection technology to remove pathogens such as C. diff, staphylococcus aureus and carbapenem-resistent Enterobacteriaceae, Terumo said. The Xenex LightStrike device has also been […]
Abbott to close $25B St. Jude buy
Abbott (NYSE:ABT) said today that it plans to close its $25 billion buy of St. Jude Medical (NYSE:STJ) next Wednesday, Jan. 4, after receiving all necessary regulatory clearances for the deal. Abbott touted the acquisition, saying it would position the combined entity to cover “nearly every area” of the cardiovascular market, holding onto the number 1 or 2 […]
Report: US regulators poised to clear Abbott’s $25B St. Jude buy
Regulators in the U.S. are positioned to approve Abbott‘s (NYSE:ABT) $25 billion acquisition of St. Jude Medical (NYSE:STJ), according to 2 Reuters sources. The approval from the U.S. Federal Trade Commission could come through as early as this week or the next, according to the Reuters report. The companies were unsure of the conditions necessary for […]
Fresenius expands prefilled syringe portfolio
Fresenius (NYSE:FMS) business group Fresenius Kabi said today that it added its heparin sodium injection to the company’s Simplist prefilled syringe portfolio. The prefilled syringe for subcutaneous and intravenous bolus injections expands Fresenius Kabi’s available Heparin formulations. The Lake Zurich-Ill. company’s Simplist syringes have a 2-year shelf life and do not require any assembly or point-of […]
Fresenius inks 5-year distro deal with Terumo to launch CATSmart in US
Fresenius (NYSE:FMS) business group Fresenius Kabi said today it inked a 5-year exclusive distribution deal with Terumo Corp. (TYO:4543) to launch Fresenius’ CATSmart autotransfusion system in the US. Autotransfusion devices are designed to re-infuse a patient’s own lost blood during surgery. Fresenius said the CATSmart is its next-gen continuous autotransfusion system, featuring continuous-flow technology, 3 wash programs, […]
Terumo moves forward on $1B deal to pick up St. Jude, Abbott vascular assets
Terumo Corp. (TYO:4543) said today it reached an agreement with Abbott (NYSE:ABT) and St. Jude Medical (NYSE:STJ) to acquire vascular products from both companies in connection to their $25 billion merger. The deal will include St. Jude’s Angio-Seal and FemoSeal vascular closure product lines and Abbott’s Vado steerable sheath. Together, the total annual sales of the businesses are approximately […]
Abbott, St. Jude Medical to deal vascular assets to Terumo for $1B
Abbott (NYSE:ABT) and St. Jude Medical (NYSE:STJ), the subject of a pending, $25 billion acquisition by Abbott, agreed to deal some of their respective vascular assets to Japan’s Terumo Corp. (TYO:4543) for about $1.12 billion. The sale involves St. Jude’s Angio-Seal and Femoseal vascular closure devices and Abbott’s Vado steerable sheath, the companies said today. Abbott […]
Terumo inks regenerative collab deal with Cognate BioServices
Terumo Corp. (TYO:4543) and Cognate BioServices said today they inked a collaborative cellular and immunotherapy products development deal. Get the rest of the story at our sister site, Medical Design & Outsourcing